IMMUNOPROPHYLAXIS OF SEVERE RESPIRATORY-SYNCYTIAL VIRAL INFECTION IN CHILDREN WITH BRONCHOPULMONARY DYSPLASIA: RESULTS OF 4 EPIDEMIC SEASONS
https://doi.org/10.15690/pf.v9i6.518
Abstract
Children with bronchopulmonary dysplasia belong to the risk group of severe respiratory-syncytial viral infection (RSV). World experience and authors' own clinical data show that seasonal immunoprophylaxis of RSV infection's severe course by palivizumab in these patients allows reducing frequency of hospitalizations, CPR conduct and fatal outcomes. The article gives data of clinical instrumental evaluation of efficacy and safety of palivizumab use in the 3 past and the 4th (current) epidemic seasons.
About the Authors
A. A. Baranov
Scientific Center of Children’s Health, Moscow, Russian Federation
I.M. Sechenov First Sechenov Moscow State Medical University, Russian Federation
Russian Federation
Russian Federation
I. V. Davydova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
T. V. Turti
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
L. S. Namazova-Baranova
Scientific Center of Children’s Health, Moscow, Russian Federation
I.M. Sechenov First Sechenov Moscow State Medical University, Russian Federation
N.I. Pirogov Russian Medical Research University, Moscow, Russian Federation
Russian Federation
Russian Federation
V. V. Altunin
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
E. P. Zimina
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
E. V. Pavlyukova
Scientific Center of Children’s Health, Moscow, Russian Federation
Russian Federation
Russian Federation
References
1. Morris J. A.Jr., Blunt R. E., Savage R. E. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp. Biol Med. 1956; 92: 544–50.
2. Notario D., Tatochenko V., Uchaikin V. et al. Epidemiology of respiratory syncytial virus in children 2years of age hospitalized with lower respiratory tract infections in the Russian Federation: a prospective, multicenter study. Clinical Epidemiolgy. 2010; 2: 221–27.
3. Simoes E. A. F., Carbonell-Estrany X. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries. Pediatr Infect Dis J. 2003; 22: 40–45.
4. Law B. J., Langley J. M., Allen U. et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004; 23 (9): 806–14.
5. Hall C. B., Weinberg G. A., Iwane M. K., Blumkin A. K., Edwards K. M., Staat M. A., Auinger P., Griffin M. R., Poehling K. A., Erdman D., Grijalva C. G., Zhu Y., Szilagyi P. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009; 360 (6): 588–98.
6. Figueras-Aloy J., Carbonell-Estrany X., Quero J. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33–35 weeks in Spain. Pediatr Infect Dis J. 2004; 23 (9): 815–20.
7. Figueras-Aloy J., Carbonell-Estrany X., Quero J. Risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J. 2008; 27: 788–93.
8. Намазова-Баранова Л. С., Турти Т. В., Давыдова И. В. и др. Флоуметрия спокойного дыхания у детей первого года жизни (методические рекомендации). Москва. 2012. 32 с.
9. Классификация клинических форм бронхолегочных заболеваний у детей. Москва. 2009. С. 9–10.
10. Boyce T. G., Mellen B. G., Mitchel E. F., Wright P. F., Griffin M. R. Rates of hospitalization for respiratory syncytial virus among children in Medicaid. J Pediatr. 2000; 137: 865–70.
11. Horn S. D., Smout R. J. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr. 2003; 43: 133–41.
12. Navas L., Wang E., de Carvalho V., Robinson J. Improved outcome of RSV infection in a high-risk hospitalized population of Canadian children. J Pediatr. 1992; 121: 348–54.
13. Greenough A. Role of ventilation in RSV disease: CPAP, ventilation, HFO, ECMO. Ped Resp Rev. 2009; 1 (10): 26–28.
14. Prince G. A., Jenson A. B., Hemming V. G. et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by intramuscular inoculation of formalin-inactivated virus. Journal of Virology. 1986; 57: 721–28.
15. Синагис (инструкция по применению). Эбботт Лэбораториз С. А.
16. Давыдова И. В., Яцык Г. В., Тресорукова О. В. и др. Клинико-функциональные особенности течения бронхолегочной дисплазии в первом полугодии жизни. Российский педиатрический журнал. 2008; 6: 10–13.
17. Impact-RSV Study Group. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization from Respiratory Syncytial Virus Infection in High-risk Infants. Pediatrics. 1998; 102: 531–37.
18. Вишнева Е. А., Намазова-Баранова Л. С., Торшхоева Р. М., Куличенко Т. В., Томилова А. Ю., Алексеева А. А., Турти Т. В. Паливизумаб: новые возможности профилактики астмы? Педиатрическая фармакология. 2011; 8 (3): 24–30.
19. Henderson J., Hilliard T. N., Sherriff A. еt al. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: A longitudinal birth cohort study. Pediatr Allergy Immunol. 2005; 16: 386–92.
20. Checchia P. A., Nalysnyk L., Fernandes A. W. et al. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receving prophylaxis with palivizumab: A systematic literature review and meta-analysis. Pediatr Crit Care Med. 2011; 12 (5): 580–89.
Review
For citations:
Baranov A.A., Davydova I.V., Turti T.V., Namazova-Baranova L.S., Altunin V.V., Zimina E.P., Pavlyukova E.V. IMMUNOPROPHYLAXIS OF SEVERE RESPIRATORY-SYNCYTIAL VIRAL INFECTION IN CHILDREN WITH BRONCHOPULMONARY DYSPLASIA: RESULTS OF 4 EPIDEMIC SEASONS. Pediatric pharmacology. 2012;9(6):48-52. (In Russ.) https://doi.org/10.15690/pf.v9i6.518
Views:
673
Email this article 